AI ScreeningAI ChatPricing
  1. JP-listed companies
  2. ASKA pharmaceutical Co., Ltd.
  3. Financials
  4. Cash and cash equivalents

ASKA pharmaceutical Co., Ltd.【JP:E00929】

Market cap
P/E ratio
SummaryFinancialsDividendsHistorySegmentsWorkforce
Period EndCash and cash equivalents (Million JPY)YoY (%)
Mar 31, 20207,294-33.58%
Mar 31, 201910,982+7.45%
Mar 31, 201810,221-30.76%
Mar 31, 201714,761+170.25%
Mar 31, 20165,462-18.77%
Mar 31, 20156,724

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)